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survival, local control or toxicity profile. Epidemiological data was 
searched to determine the proportion of new cases of cancer with 
each indication. Patient preference data were included for breast and 
prostate cancers. Indications and epidemiological data were reviewed 
by a court of external reviewers. Univariate and Monte Carlo 
simulations were used in sensitivity analysis. 
Results: Over 600 papers and guidelines were reviewed for 20 cancer 
sites. The proportions of cancer types had changed markedly over 10 
years. Prostate cancer increased from 12% of all cancers to 18%. The 
guidelines suggest that 48.6% of new cases of cancer have an 
indication for radiotherapy (with or without chemotherapy) at least 
once in the course of their illness. The range was from 0% for liver 
cancer to 94% for vaginal cancer. 9.1% of cases had an indication for 
synchronous chemoradiotherapy. 
Conclusions: The small decrease in optimum radiotherapy utilisation 
rate was mostly due to changes in the proportions of cancer in the 
population and the removal of a small numberof indications for 
radiotherapy.  
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Purpose/Objective: Documenting key parameters for the activity, 
utilization and infrastructure of radiotherapy in Europe is an impor-
tant part of HERO - the ESTRO Health Economics in Radiation Oncology 
project [1]. HERO has the overall aim to develop a knowledge base of 
the provision of radiotherapy in Europe and build a model for health 
economic evaluation of radiation treatments at the European level. 
The aim of the current report is to describe the initial analysis of a 
pan-European survey of radiotherapy activity and infrastructure. 
Materials and Methods: Contact persons representing the national 
societies within radiation oncology in 42 European countries were 
identified from the ESTRO database and personal contacts. The con-
tact persons were asked to respond to an 84-item web-based ques-
tionnaire detailing epidemiology (population, cancer types and cases 
per year), radiotherapy activity (number of courses, number of pa-
tients treated), infrastructure (departments and technology), staffing 
and economics (public/private facilities, type of reimbursement), all 
on a national level. By December 2012, a total of 29 European coun-
tries have entered their data. 
Results: A large variation between countries was found for most 
parameters studied. Between countries the proportion of annual 
patients treated with radiotherapy relative to all new cancer cases 
varied from 20% to 55% (median 39%); the number of MV machines per 
million inhabitants from 1.25 to 9.62 (median 5.29) and the average 
number of MV machines per department from 0.8 to 8.0 (median 2.0). 
The average number of patients treated per year per MV machine 
varied from 205 to 862 (median 325), per radiation oncologist (89 to 
266; median 167), per radiation physicist (121 to 435; median 263), 
and per radiation therapist (23 to 595; median 101). 
Conclusions: The initial results of this survey have documented an 
enormous heterogeneity, in the order of a factor of 3-5, in all key 
parameters related to activity, utilization, infrastructure and staffing 
of radiotherapy in Europe. Radiotherapy seemed to be underutilized in 
most countries when compared to evidence based data from CCORE 
[2], although there has been a positive evolution in availability and 
infrastructure compared to the earlier studies [3,4]; the European 
average number of MV machines per million inhabitants and per 
department is now in line with QUARTS recommendations [4]. The 
data will be further analyzed in the context of the ESTRO HERO 
project, in collaboration with the national societies and the Interna-
tional Atomic Energy Agency. 
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Purpose/Objective: ESTRO has launched the Health Economics in 
Radiation Oncology (HERO) project to develop a knowledge base and a 
model for health economic evaluation of radiotherapy (1). In this 
framework, the need for radiotherapy will be assessed in order to 
explore the optimum radiotherapy utilization in Europe. The percen-
tage of new cancer patients who require radiotherapy relative to the 
total number of cancer patients (Attributable Radiotherapy Percen-
tage, ARP) is one of the usual measures for planning purposes of 
radiotherapy equipment and staffing. The objective of this work was 
to assess the variability of ARP according to the differences in propor-
tional incidence and in stage at diagnosis by country in Europe. 
Materials and Methods: Decision trees from the Australian CCORE-
projectwere used to assess the percentage of patients requiring 
evidence-basedradiotherapy (2). The original incidence data were 
substituted with theproportional distribution of cancers in different 
European countries, based onincidence data for 2008 from Globocan 
(www.iarc.fr). Available data on population-based stage at diagnosis 
were used for head and neck, lung, breast, prostate and rectal cancer 
in selected countries, used for exploratory purposes. The analysis was 
carried out with TreeAge software. 
Results: The range of values of ARP among European countries varied 
from 52% to 57% of new cancer cases. Stage at diagnosis also contri-
buted to the variability of ARP estimates with a range from 2% in 
breast cancer to 15% in rectal cancer. Most relevant factors influen-
cing the ranges of values observed were due to the percentage of 
cases diagnosed at earlystage with surgery as the only treatment in 
rectal cancer; and the important variability in the incidence by coun-
try of head and neck cancer and prostate.These estimates were 
evidence based and did not take into account clinical problems such 
as comorbidity that could influence the decision for treatment. Also, 
the number of patients that could require retreatment is not included 
in the estimate. Both factors could modify significantly the final ARP 
percentage of incidence cases for planning radiotherapy in a specific 
country. 
Conclusions: ARP is a useful indicator for assessing the needs for 
radiotherapy; however, national differences in the incidence of 
cancer and stage at diagnosis should be taken into account in order to 
make a more realistic estimate for planning purposes. The range 
observed betweencountries and tumour stages could translate into a 
significant change in the number of facilities required. 
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Purpose/Objective: Delaney et al (2003) estimated that more than 
half of all cancer patients should receive radiotherapy at some point 
during the course of the disease. Actual Radiotherapy Utilization 
(RTU) rates are usually lower than the optimal rates 
Our objectives were: 
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1) To calculate the actual RTU rates in NSW & ACT (2004-06) directly 
from patient treatment records with special emphasis on the effect of 
geographic variation on RTU. 
2) To identify factors affecting RTU 
Materials and Methods: Radiotherapy treatment data were collected 
from all 17 radiotherapy departments (RTD) in NSW and ACT for the 
period January 2004-June 2007. Through Center for Health Record 
Linkage, the radiotherapy data and Central Cancer Registries (CCR) 
records in NSW & ACT were linked. . All patients' residential addresses 
were geocoded. A Geographic Information System (GIS) software was 
used to calculate the road distance between patients' residential 
address and the closest RTD. Patients were excluded from the study if 
their nearest RTD was outside NSW or ACT. 
Results: The overall raw RTU rate in NSW and ACT (2004-06) was 32%. 
After data linkage with CCR records, the overall RTU rate was 24% for 
unique patients diagnosed and received radiotherapy within the study 
period. Excluding patients at the borders with other States, the RTU 
rate was 26%. The RTU rates decreased with increasing distance from 
patient residence to the nearest radiotherapy facility (p <0.0001). 
RTU ranged from 27% for those who lived less than 50 km to 19% for 
those who lived 400+ Km from the nearest RTD. Older patients were 
less likely to receive RT than younger ones (p<0.001) and female 
younger patients were more likely to receive RT than younger males 
(p<0.001). Our study did not show a correlation between receiving RT 
and the socioeconomic status of patients using Index of Relative 
Socioeconomic Disadvantage quintiles.  
Conclusions: This is the first study to use data linkage to match 
radiotherapy treatment data received from all RTD to all CCR records 
in NSW and ACT. It is also the first study to calculate the road 
distance between patient residence and the nearest radiotherapy 
facility. There was a statistically significant difference in radiotherapy 
access based on road distance. 
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Purpose/Objective: To estimate the expected comparative 
costs/Quality Adjusted Life Year (QALY) gained of the guideline 
recommended treatments Active Surveillance (AS), Radical 
Prostatectomy (RP), Brachytherapy (BT), EBRT and appropriate 
combinations hereof incl. Androgen Deprivation Therapy (ADT) in 
patients with low, intermediate or high risk prostate cancer over a 
time horizon of 10 years from an UK-NHS cost perspective. 
Materials and Methods: A decision analytic model was developed 
considering survival, health related quality of life and costs associated 
with 1) initial treatment and 2) management of relapse, local 
recurrence, metastasis, and 3) treatment-associated complications 
and morbidities. The wide range of appropriate treatments to be 
compared for low, intermediate and high risk prostate cancers were 
based on NICE, EAU, AUA and NCCN guidelines. Survival, relapse, 
recurrence, metastasis and complication rates, as well as health-
related quality of life and cost data were based on systematic reviews 
of the published literature and expert opinions where required. 
Probabilistic sensitivity analysis, using 10000 Monte Carlo simulations, 
quantified the joint decision uncertainty surrounding model outcomes 
at the prevailing threshold of £20k-30k/QALY. 
Results: In low risk prostate cancer, AS has the highest probability for 
being cost-effective (C/E), i.e. 70%. When AS is unacceptable to a 
patient, BT dominates EBRT by generating more QALYs/patient 
(+0,06) at lower cost (-£14k) over 10-years. EBRT is C/Evs. RP as 
shown by the incremental C/E ratio of £7k/QALY which is far below 
the WTP threshold. In intermediate risk, EBRT+BT is the dominating 
treatment (5,02QALYs at £14.7k; 65% probability C/E), followed by BT 
as monotherapy (4,98QALYs at £16.9k; 35% probability C/E). RP 
generates the lowest QALYs at relatively high costs (4,06 QALYs, 
£28.8k). In high risk, all mono and combination radiation treatments 
dominate RP which generates 3,96 QALYs at £35.4 over 10 
years/patient. EBRT+BT (4,7 QALYs, £35.1k) is most C/E compared to 
monoradiation treatments by generating more QALYs at only slightly 
higher total costs. BT (4,65 QALYs, £32.5k) dominates EBRT (4,62 
QALYs, £32.5k) and EBRT+ADT(4,47 QALYs, £37.7k). 
Conclusions: Across risk groups, RP is likely to perform worse than 
radiation treatments in terms of expected costs/QALY. In 
intermediate and high risk prostate cancer, EBRT+BT is expected to 
provide highest QALYs at acceptable or lower cost than monoradiation 
treatments and RP. In low risk prostate cancer, AS is preferred in 
terms of QALYs, while BT dominates EBRT and RP in terms of 
costs/QALYs.  
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Purpose/Objective: In the framework of a feasibility study for a 
hadron therapy centre in Belgium, cost calculations are performed by 
means of two separate models, with the aim to determine the 
treatment cost per patient and to estimate the need for 
reimbursement for different technical solutions. 
Materials and Methods: The Business Model (BM) analyses the 
financial implications of setting up a facility over time, taking into 
account all costs incurred from the preparatory phase, first 
investment and commissioning, over the ramp-up period where the 
centre starts to accrue patients, until operation at full capacity and 
beyond. The Activity-Based Costing (ABC) model calculates the costs 
for a centre in a specific year corresponding to a steady state of 
operation. Both models analyse private financing compared to 
financing with public investment to cover investment costs. Three 
different technical solutions are considered, all with two treatment 
rooms: a combined proton/carbon ion centre, a dedicated carbon ion 
and a dedicated proton centre. Input parameters for both models 
(investment and operational costs, patient population, fractionation 
schedules and time slots) are derived from discussions with 
international experts and literature. 
Results: The total investment cost ranges from 51,5 M€ for a 
dedicated proton centre up to 101,5 M€ for a combined centre. The 
annual operational cost is influenced by the financing system and 
ranges from 10,0 M€ (proton centre, public financing) up to 24,8 M€ 
(combined centre, private financing). 
Table 1 summarizes the required reimbursement per patient 
necessary to yield a positive cumulative net cash flow after 16 years 
of operation using the BM, and the average cost per patient and cost 
per type of treatment and fraction using the ABC model. Costs are 
expressed in Euro for the year 2012.  
 
 
As they disregard the impact of inflation, the costs calculated with 
ABC are lower than the required reimbursement based on the BM.  
Sensitivity analyses show that the required reimbursement for 
privately financed centres is highly sensitive to the delay in 
commissioning and to the interest rate. Uncertainties in investment 
cost have a greater impact on treatment cost and required 
reimbursement than changes in personnel costs. Operating scenario, 
product mix and fractionation schedules have a significant impact on 
the cost per treatment and per fraction. 
Conclusions: To align costs to European reimbursement rates, our 
calculations suggest that the financially most attractive option for 
Belgium is a dedicated carbon ion centre with public financing. The 
choice however also depends on the clinical indications and the socio-
political context. 
   
  
